Two genes that help to control the human body’s biological clock are dysregulated in myasthenia gravis (MG) — a disease marked by symptoms that often grow worse throughout the day — according to the findings of a new study from China. Study data indicated that dysregulation of these genes,…
News
People with generalized myasthenia gravis (gMG) can carry certain types of self-reactive antibodies — proteins that mistakenly target the body’s own cells and tissues — that drive the disease but are treatment resistant, according to a new study by Yale School of Medicine researchers. These self-reactive antibodies, or autoantibodies,…
Treatment with gefurulimab, an experimental self-administered injection therapy, outperformed a placebo in easing symptoms of generalized myasthenia gravis (gMG) among people with the chronic autoimmune disease, the results of a Phase 3 clinical trial show. The trial met both its primary and secondary endpoints, or goals, with treatment…
A case report from Germany showed that two women with severe, treatment-resistant myasthenia gravis (MG) responded well to blinatumomab, suggesting the anti-cancer medication may offer a new option for hard-to-treat autoimmune diseases. “Since this first-in-human experience comprises two cases, our findings should be viewed as proof-of-concept rather than evidence…
Surgery to remove the thymus gland led to a long-term reduction in levels of immune T-cells and to temporary changes in levels of proteins involved in regulating immune and inflammatory responses in people with myasthenia gravis (MG), a study shows. There were no significant effects on the levels of…
A higher body mass index (BMI), a measure of body fat based on height and weight, is associated with an increased risk of progression from ocular to generalized myasthenia gravis (MG), according to a study in China. Ocular MG is a type of MG in which muscle weakness…
Daily treatment with Zilbrysq (zilucoplan) was safe and effective in people with generalized myasthenia gravis (gMG) who were switching from Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz), according to results from a small U.S. clinical trial. All of these medications belong to a class of therapies…
Azathioprine did not outperform standard treatment in helping adults with myasthenia gravis (MG) live longer, and while older age alone increased the risk of death, using azathioprine for many years was linked to serious blood problems and cases of cancer, a study has found. However, “although the use of…
Povetacicept, a treatment for autoimmune diseases in the pipeline of Vertex Pharmaceuticals, reduced disease activity in a study with a mouse model of myasthenia gravis (MG) by lowering the levels of disease-causing antibodies in the bloodstream. Researchers also observed that povetacicept outperformed efgartigimod — approved as Vyvgart…
Treatment with Vyvgart (efgartigimod) eased hard-to-treat symptoms for a trio of women with generalized myasthenia gravis (gMG) who tested negative for three antibodies commonly seen in the disease, according to a case series from China. Per the researchers, “this report describes three patients with triple-[seronegative] gMG successfully treated with efgartigimod,”…
Recent Posts
- Recovering from a myasthenia gravis crisis that sent me to the ICU
- MGFA Session 2026: Repeat CAR T-cell care eases gMG for some
- MDA Engage: ‘I am not alone’ was the biggest takeaway in Chicago
- Living with myasthenia gravis makes me skilled at the art of anticipation
- MGFA Session 2026: Treatment cuts gMG hospitalization rates